All the Active Ingredient Drugs
Nucleoside and Nucleotide Reverse Transcriptase Inhibitors. Abacavir 600 mg, Lamivudine 300 mg. The recommend. dose for Adult. and child. >12 weigh. at least 40 kg, is1 tab×1/d. See lit. Tmt. of HIV infec. in adult. and in child. over the age of 12 yrs.
Antivirals for Treatment of HIV Infections, Combinations. Abacavir (as sulfate) 600 mg, Lamivudine 300 mg, Dolutegravir (as sodium) 50 mg. F.C. TAB: 30. 1 tab x 1 dly. Renal impairm.:
not recom. in pts. with CLcr < 50 ml/
min. Hepatic impairm.: see lit.
Treat. of HIV infec. Adults and adolesc.
above 12 yrs weigh. at least 40 kg.
C/I: Hypersens. to dolutegravir, abacavir
or lamivudine or to any of the excip.
Co-administ. with dofetilide.
Nucleoside Reverse Transcriptase Inhibitor. Abacavir (as sulfate) 300 mg, Lamivudine 150 mg, Zidovudine 300 mg. F.C. TABS: 60. 1 tab 2 x dly with or
without food. Start tmt. with the 3
components separately for first 6-8
wks then transfer to fixed comb. Child.
under 18 yrs not recommend.
Tmt. of HIV infect. in adults.
C/I: Hypersens., espec. hypersensitivity
reactions, end-stage renal dis.;
neutrophil count < 0.75 x 10^9/l or
Hg. levels < 7.5g/dl or 4.65 mmol/l.
Nucleoside Reverse Transcriptase Inhibitor. Abacavir 300 mg. F.C. TAB.:60. Adults, adolesc, child, (wt. at least 25 kg): The recomm. dose is 600 mg dly. This may be admin. as either 300 mg (1 tab×2/d or 600 mg (2 tabs). once dly. Child. (wt.<25 kg): Dosing accord. to wt. bands is recom. for tabs.
Child. wt. ≥20 kg - <25 kg: The recom. dose is 450 mg dly. This may be admin. as either one 150 mg (0.5 tab.) taken in the morn. and 300 mg taken in the eve., or 450 mg (1.5 tabs.) taken once dly.
Child. wt. 14 to< 20 kg: The recomm. dose is 300 mg dly. This may be admin. as either 150 mg (0.5 tab.) ×2/d or 300 mg×1/d.
Indicated in antiretrovir. comb. ther. for the tmt. of HIV infec. The demonstrat. of the benefit of Abacavir is mainly based on results of studies performed with a twice daily regimen, in tmt.-naïve adult pts. on comb. ther..
Before initiat. tmt. with abacavir, screen. for carriage of the HLA-B*5701 allele should be performed in any HIV-infected pt., irrespective of racial origin. Abacavir should not be used in pt. known to carry the HLA-B*5701 allele.